Encuentro de Investigación Buscando sinergias

Alicante | 7 de junio de 2022 Hospital General Universitario Dr. Balmis de Alicante. Salón de actos. De 10:00 h. a 13:30 h.



Inmunología del Carcinoma Hepatocelular

José Manuel González Navajas. Grupo de Inflamación y Progresión a Cáncer Hepático e Intestinal

ISABIAL. E-mail: gonzalez_josnav@gva.es

Research Interests

We are interested on how the immune system can either fight or promote tumors and how this knowledge can be translated into useful approaches to prevent or treat cancer. Our current projects study the role of the Inflammasome

complex during chronic liver inflammation and cancer, and the impact of CD4+ T helper 17 (Th17) cells on the development of liver cancer and the efficacy of immune checkpoint inhibition therapy. In particular, our active research projects are:

- Inflammasome activation and pyroptosis in hepatocellular carcinoma
- Role of IL-1R/IL-1RAP signaling in the efficacy of immune checkpoint inhibition (ICI) therapy
- The salt-Th17 axis in HCC development and the response to ICI immunotherapy
- Identification of T cell-associated makers of response to immunotherapy in HCC
- Harnessing T regulatory (Treg) cells to reduce non-alcoholic fatty liver disease (NAFLD)-associated HCC





- Team Composition: our team includes both basic/translational and clinical scientists
 - Beatriz Lozano (Lab Manager)
 - Amalia Tzoumpa (PhD student)
 - Yin Huang (PhD student)
 - Joanna Picó (PhD student)
 - M. Teresa Pomares (Nurse)
- Sonia Pascual (Clinician Hepatologist)
 - Pablo Bellot (Clinician Hepatologist)
 - Iván Herrera (Clinician Hepatologist)
- Cayetano Miralles (Clinician -Hepatologist)
 - José M. González-Navajas (PI)

We are particularly interested in collaborations...

...with groups that are experienced in:

- Targeted drug delivery and Nanotechnology



- Organoids

- 0

- CAR T cells
- Humanized mouse models

"Sometimes I think that our collaboration would work better without you"



